Research Topics
Species | Julie R BrahmerSummaryAffiliation: Johns Hopkins University Country: USA Publications
| Collaborators
|
Detail Information
Publications
Non-small cell lung cancer: adjuvant and neo-adjuvant chemotherapyJulie R Brahmer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Respirology 12:320-5. 2007..Data are presented to support the standard use of adjuvant therapy in patients with stage II and III disease, as well as data supporting the use of neo-adjuvant therapy in selected patients with non-small cell lung cancer...- Adjuvant therapy for resected non-small-cell lung cancer: recent advances, emerging agents, and lingering questionsTara L Lin
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room G-94, Baltimore, MD 21231-1000, USA
Curr Oncol Rep 6:251-8. 2004..We also address the most effective and least toxic regimens for adjuvant chemotherapy and the subsets of patients likely to derive the most benefit... 
Harnessing the immune system for the treatment of non-small-cell lung cancerJulie R Brahmer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
J Clin Oncol 31:1021-8. 2013..These therapies alone or in combination may hold the key to making immunotherapy a reality in the treatment of lung cancer...
Sex differences in outcome with bevacizumab therapy: analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 459Julie R Brahmer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
J Thorac Oncol 6:103-8. 2011..Bevacizumab improved overall survival. However, an unplanned subset analysis did not show a survival benefit for females treated with bevacizumab...- Concordance of cancer patients' function, symptoms, and supportive care needsClaire F Snyder
Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
Qual Life Res 18:991-8. 2009..Although patients' function, symptoms, and supportive care needs are obviously related, a better understanding of these relationships could improve patient management... - Needs assessments can identify scores on HRQOL questionnaires that represent problems for patients: an illustration with the Supportive Care Needs Survey and the QLQ-C30Claire F Snyder
Johns Hopkins School of Medicine, 624 N Broadway, Room 657, Baltimore, MD 21205, USA
Qual Life Res 19:837-45. 2010..We explored using needs assessments to identify HRQOL scores associated with patient-reported unmet needs... - Symptoms, supportive care needs, and function in cancer patients: how are they related?Claire F Snyder
Johns Hopkins School of Medicine, Baltimore, MD, USA
Qual Life Res 17:665-77. 2008..To explore the associations among symptoms, supportive care needs, and function... - Safety and activity of anti-PD-L1 antibody in patients with advanced cancerJulie R Brahmer
Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231, USA
N Engl J Med 366:2455-65. 2012..Blockade of interactions between PD-1 and PD-L1 enhances immune function in vitro and mediates antitumor activity in preclinical models... - Safety, activity, and immune correlates of anti-PD-1 antibody in cancerSuzanne L Topalian
Department of Surgery, Johns Hopkins University School of Medicine and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
N Engl J Med 366:2443-54. 2012..Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1... - Comparative pharmacokinetics of weekly and every-three-weeks docetaxelSharyn D Baker
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
Clin Cancer Res 10:1976-83. 2004..The comparative pharmacokinetics of docetaxel during weekly and once every 3 weeks (3-weekly) administration schedules were evaluated... - Adjuvant treatment in non-small cell lung cancer: Where are we now?Rosalyn A Juergens
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 401 North Broadway, Johns Hopkins, Baltimore, MD 21205, USA
J Natl Compr Canc Netw 4:595-600. 2006..Cisplatin-based therapy has now been shown to provide a significant survival benefit in several trials and recent meta-analyses. These data have changed the paradigm for how early-stage lung cancer is managed... - Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumorsPatricia M LoRusso
Karmanos Cancer Institute, Detroit, Michigan Johns Hopkins University, Baltimore, Maryland, USA
Clin Cancer Res 17:2502-11. 2011..This phase I trial assessed GDC-0449 treatment in patients with solid tumors refractory to current therapies or for which no standard therapy existed... - Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJulie R Brahmer
Johns Hopkins University School of Medicine, and the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
J Clin Oncol 28:3167-75. 2010..This phase I study sought to determine the safety and tolerability of anti-PD-1 blockade in patients with treatment-refractory solid tumors and to preliminarily assess antitumor activity, pharmacodynamics, and immunologic correlates... - Adjuvant therapy for resected non-small-cell lung cancer: past, present, and futureRosalyn A Juergens
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 2410, USA
Curr Oncol Rep 7:248-54. 2005..The goal of this paper is to review the data on adjuvant therapies that have emerged over the past 30 years, focusing specifically on the trials that have been published in the past 5 years... - Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancerMichael A Carducci
Division of Medical Oncology, Kimmel Cancer Center at Johns Hopkins, Baltimore, MD, USA
J Clin Oncol 24:4092-9. 2006..Enzastaurin is well tolerated up to 700 mg/d. Evidence of early activity was seen with significant stable disease... - Optimizing the dose and schedule of anti-vascular endothelial growth factor antibodies in non-small-cell lung cancerJustin F Klamerus
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA
Clin Lung Cancer 9:S51-6. 2008..Many questions remain, such as the role of the anti-VEGF antibody in early-stage disease, the safety of bevacizumab in patients with squamous histology NSCLC, and the benefit of combination therapy in elderly patients... - Chemotherapy for advanced stage non-small cell lung cancerAmir T Fathi
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
Semin Thorac Cardiovasc Surg 20:210-6. 2008..Clinical trials have also recently demonstrated increased efficacy for agents such as docetaxel and pemetrexed in the second line setting for refractory disease... - Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicityCharles M Rudin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, David H Koch Cancer Research Building, Room 544, 1550 Orleans St, Baltimore, MD 21231, USA
J Clin Oncol 26:1119-27. 2008..To assess the pharmacogenomic and pharmacokinetic determinants of skin rash and diarrhea, the two primary dose-limiting toxicities of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib... - "Who should receive epidermal growth factor receptor inhibitors for non-small cell lung cancer and when?"Christine L Hann
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
Curr Treat Options Oncol 8:28-37. 2007..Prospective trials are ongoing to determine which patient and tumor characteristics are predictive of a clinical benefit from TKI therapy... - Second-line Therapy for advanced non-small-cell lung cancerChristine L Hann
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231-1000, USA
Curr Oncol Rep 8:243-7. 2006..In 2004, two additional agents, pemetrexed and erlotinib, also received approval, giving patients three options for second-line treatment. Many promising new drugs and drug combinations are currently under investigation... - Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 AntibodyEvan J Lipson
Authors Affiliations Departments of Oncology, Urology, Dermatology, Pathology, and Surgery, Johns Hopkins University School of Medicine and Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland and Department of Internal Medicine, Wayne State University School of Medicine and Henry Ford Hospital, Detroit, Michigan
Clin Cancer Res 19:462-8. 2013..Here, we provide long-term follow-up on three patients from that trial who sustained objective tumor regressions off therapy, and test the hypothesis that reinduction therapy for late tumor recurrence can be effective... - Update in oncologyJulie R Brahmer
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland 21231-1000, USA
Ann Intern Med 143:587-92. 2005 - Asking the right questions: investigating needs assessments and health-related quality-of-life questionnaires for use in oncology clinical practiceClaire F Snyder
Division of General Internal Medicine, Johns Hopkins School of Medicine, 624 N Broadway, 6th Floor, Baltimore, MD 21205, USA
Support Care Cancer 15:1075-85. 2007..We investigated the item content from two health-related quality-of-life (HRQOL) questionnaires and two needs assessments for this purpose... - Antiangiogenic agents in combination with chemotherapy in patients with advanced non-small cell lung cancerSusanna V Ulahannan
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University Hospital, Baltimore, Maryland, USA
Cancer Invest 29:325-37. 2011..Here we review current clinical data with combination therapy involving antiangiogenic agents and cytotoxic chemotherapy in patients with advanced NSCLC... - Delayed diagnosis and elevated mortality in an urban population with HIV and lung cancer: implications for patient careMalcolm V Brock
Johns Hopkins Hospital, and Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21287, USA
J Acquir Immune Defic Syndr 43:47-55. 2006..Lung cancer is more common in HIV-infected patients than in the general population. We examined how effectively lung cancer was being diagnosed in our HIV-infected patients... - Phase I study of docosahexaenoic acid-paclitaxel: a taxane-fatty acid conjugate with a unique pharmacology and toxicity profileAntonio C Wolff
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and The Johns Hopkins University School of Medicine, Baltimore, Maryland, 21230 1000, USA
Clin Cancer Res 9:3589-97. 2003..This Phase I trial examined its toxicity and pharmacokinetics (PKs)... - Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancerMark A Socinski
Multidisciplinary Thoracic Oncology Program, Lineberger Comprehensive Cancer Center, University of North Carolina, CB 7305, Chapel Hill, NC 27599, USA
J Clin Oncol 26:650-6. 2008.... - Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599Suresh S Ramalingam
Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, USA
J Clin Oncol 26:60-5. 2008..We conducted a subset analysis of ECOG 4599 to determine the outcome for elderly patients... - Determination of the docetaxel vehicle, polysorbate 80, in patient samples by liquid chromatography-tandem mass spectrometryAlex Sparreboom
Laboratory of Experimental Chemotherapy and Pharmacology, Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek and University Hospital Rotterdam, Groene Hilledijk 301, The Netherlands
J Chromatogr B Analyt Technol Biomed Life Sci 773:183-90. 2002..Our current method is approximately 60-100-fold more sensitive than previous assays, and will be used to define Tween 80 disposition in patients receiving Taxotere...